Coccidiosis control for breeding and laying chickens requires the development of immunity against multiple Eimeria species. Only one vaccine was widely available to producers in the European Union (EU) from 1991 until 2015. Recently, 2 new products have been introduced to the market. The 3 vaccines were compared with respect to the onset of immunity in pen studies, where sample birds were challenged at 21, 25, 28, and 32 d of age to determine the time at which lesion scores became significantly different from unvaccinated controls, the "onset of immunity." The vaccines were given by oral gavage to eliminate any effect of application methodology on the onset of immunity. "Complete Immunity," defined as no coccidiosis lesions following challenge, was only achieved for one species (Eimeria tenella) by one vaccine through the final challenge at 32 d. Immunity remained incomplete for all other challenge groups for the duration of the experiment. Onset of immunity was detected by 25 d of age in only one vaccine group for all 5 challenge species tested (E. acervulina, E. maxima, E. tenella, E. necatrix, E. brunetti); and while onset of immunity was detected for some species with the other vaccines by 21 to 32 d of age, neither of the other 2 vaccines demonstrated onset of immunity to all 5 challenge species by the end of the experiment. Delayed onset of immunity could adversely affect pullet weight with early field challenge, as indicated by bird weights taken before and after challenge.
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The replacement pullet industry depends upon acquired immunity to protect flocks against these parasites [2, 5] . Rapid onset of acquired immunity helps to protect flock uniformity by preventing pullet weight loss due to field exposure to Eimeria parasites. Immunity is speciesand sometimes strain-specific [6, 7] and is developed via trickle infections [8] created either by vaccination [9] with live sporulated oocysts, or by controlled natural exposure with step-down doses of an anticoccidial drug to control field infection until immunity develops [10] .
One method of stimulating immunity is to use an attenuated, live, sporulated oocyst vaccine developed with precocious Eimeria species. Precocious strains are missing one or more schizogony stages compared to the normal life cycle of the parent Eimeria strain, and thus have a shortened pre-patent period and a significantly reduced oocyst output. The development of precocious Eimeria isolates through serial selection of the earliest oocysts shed by infected birds was described by researchers in the mid-1970s through mid-1980 [11] [12] [13] [14] [15] [16] [17] [18] . The more precocious an isolate is, the less pathology is induced by asexual stages, and the fewer oocysts are shed. The precocious strains are still capable of inducing a protective immune response to challenge with the parent strains under laboratory and field conditions, but the onset of immunity between different precocious vaccines or precocious isolates with non-homologous challenge strains has not previously been compared under controlled conditions.
The immune response to vaccination with live coccidiosis vaccines under field conditions depends upon repeated reinfection through ingestion of sporulated oocysts shed through the feces of the vaccinates into the poultry house environment [8] . Excessive reduction of oocyst output through precocity or reduced sporulation due to dry environmental conditions may hinder this process and delay the onset of immunity [19, 20] . Uneven hatchery or field application or uneven uptake of the fecal oocysts in the field environment can occasionally result in naïve or partially immune birds that can become exposed to wild Eimeria spp. in the house, or to higher doses of oocysts shed by properly vaccinated hatch-mates after the first Eimeria life cycle has been completed [21] . This study was designed to control these variables when comparing different vaccines for onset of immunity. It should be remembered that these variables will impact the behavior of the vaccines under field conditions. [28] . At the time that the experiment was conducted, these 2 products were identified by the stated brand names. They are currently labeled Huveguard R MMAT and Huveguard R NB. The paper and the figures use the original designation for ease of identification. Together, the Huveguard R products provide protection for the common challenge species of breeder and layer replacements. In this study, when both Huveguard products are given simultaneously, they will be abbreviated HSP, and when they are given according to label direction, they will be abbreviated HS+P.
The aim of this study was to compare Paracox R (P), Evalon R (E) and Huveguard R Start and Huveguard R Plus (HSP or HS+P) onset of immunity to a heterologous challenge.
MATERIALS AND METHODS
The guidelines presented in the Guide for the Care and Use of Agricultural Animals in Research and Teaching, 3rd Edition, 2010 [29] were followed.
One thousand, two hundred fifty (1250) male Cobb 500 broilers were placed in floor pens with 25 birds per pen, with 10 pens per treatment group. Three of the treatment groups (P, E, HSP) were gavaged with one dose of vac- cine at 1 d of age. One treatment group (HS + P) was gavaged with Huveguard R Start at 1 d of age and Huveguard R Plus at 14 d of age. All vaccines were purchased commercially and were used prior to the expiration date. The fifth treatment group consisted of unvaccinated controls, which were housed separately to avoid crosscontamination.
Gavage was chosen as the route of administration to eliminate variability that might be caused by mass-administration methods such as water, spray or gel application. Because this study was measuring onset of immunity, the Huveguard vaccines were given at 1 d of age together, to allow E. necatrix and E. brunetti to have the same development time as those species in vaccines P and E. In a second group, the authors administered the products with label-recommended timing, in case it provided an advantage for the onset of immunity of those species.
The birds were allowed to develop immunity in the floor pens through natural re-exposure to the vaccine oocysts shed in the feces after vaccination ("vaccine cycling"). Pooled fecal samples were hand-collected, representing each pen beginning at d 7, and every 3 d thereafter until d 40. Fecal samples were subjected to a salt solution for floatation, and samples were enumerated using a McMaster counting chamber using techniques described in Holdsworth et. al. [30] . Total oocyst counts were determined per gram of feces to ensure that the vaccine cycling was occurring and to monitor peak and decline of oocyst shedding as immunity developed. When the immunity has completely developed, oocyst shedding will decline to near-zero [31] .
At d 21, 25, 28, and 32, 2 birds per pen from each treatment group were weighed (start weight). One of those birds was challenged with a mixture of E. acervulina, E. maxima, and E. tenella (field isolates from a commercial broiler operation in Texas). The second bird was challenged with a mixture of E. necatrix and E. brunetti (field isolates from a commercial layer facility in Iowa). The challenge dose (oocysts per bird) of each species was E. acervulina, 100,000; E. maxima, 50,000; E. tenella, 75,000; E. necatrix, 50,000; and E. brunetti, 50,000.
At 7 d post-challenge, the challenged birds and negative controls were weighed to determine weight gain during the challenge period. The birds were humanely sacrificed by cervical dislocation and the coccidiosis lesions were scored by the Johnson and Reid method [32] . The number of birds used for challenge was reduced by challenging birds with multiple strains: the distinctive location and lesion characteristics within the intestines enabled the authors to distinguish each Eimeria challenge species. The lesion scorer was blinded to the vaccine group being scored.
At the end of the study (d 40), the remaining vaccinated but unchallenged birds in the pens were weighed to determine the effect of vaccination alone on weight gain compared to unvaccinated, unchallenged control birds.
In this trial, complete immunity is defined as 100% of birds with lesion score zero (0) following challenge. Onset of immunity is defined by the age at which a statistical difference in lesion scores (P < 0.01) vs. unvaccinated, challenged controls is detected.
All analyses and graphs were performed using the R language and environment for statistical computing and graphics. Average daily gain data was analyzed by one-way analysis of variance. Homogeneity of variances was evaluated. Discontinuous lesion scores were analyzed by non parametric analysis of variance using the Kruskal-Wallace rank sum test. Oocyst per gram data was analyzed by linear regression.
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RESULTS AND DISCUSSION
The onset of immunity is summarized in Figure 1 . The onset of immunity, by species, with respect to vaccine P was: E. maxima and E. tenella-d 21 Weight gain after challenge was considered in addition to lesion scores, and can be found in Tables 1 and 2 . By d 25, all of the vaccine groups had significantly better weight gain post-NB challenge vs. unvaccinated controls. By d 32, vaccine P and vaccine E had significantly better weight gain post-acervulina/maxima/tenella (AMT) challenge vs. unvaccinated controls. Figure 4 depicts the oocyst shedding patterns of the unchallenged vaccines. The regression analysis of log 10 OPG (oocysts per gram of feces) as a function of time, given treatment, indicates that vaccine E (P = 0.02), HPS and HP+S (P < 0.001) showed a significantly slower increase in OPG as well as a significantly slower decrease in OPG (P ≤ 0.001) when compared to Vaccine P. This correlates to the slower onset of immunity as demonstrated by lesion scores in response to challenge. Figure 5 depicts the final weights of unchallenged vaccinates and controls at the termination of the experiment on d 40. Despite the recycling of attenuated vaccine oocysts, there was no significant difference in the weight of the vaccinated groups and the unvaccinated control birds. [19] . Faster recycling of the vaccine means less time for environmental variability to have a negative influence on immunity development.
CONCLUSIONS AND APPLICATIONS

